Emergent BioSolutions (NYSE:EBS) Releases Earnings Results, Beats Estimates By $0.40 EPS

Posted by Nicole Kennedy on Mar 3rd, 2025

Emergent BioSolutions (NYSE:EBS – Get Free Report) issued its quarterly earnings results on Monday. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40, Zacks reports. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period last year, the company earned ($0.77) earnings per share. Emergent BioSolutions updated its FY 2025 guidance to EPS.

Emergent BioSolutions Trading Down 8.4 %

Shares of EBS stock traded down $0.63 during trading hours on Monday, reaching $6.85. The company had a trading volume of 1,560,984 shares, compared to its average volume of 2,664,738. Emergent BioSolutions has a 1-year low of $1.82 and a 1-year high of $15.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The firm has a market cap of $371.16 million, a price-to-earnings ratio of -1.67 and a beta of 1.62. The company has a 50 day moving average of $9.54 and a 200 day moving average of $9.09.

Analysts Set New Price Targets

Several research firms have recently commented on EBS. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Benchmark raised their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Monday, February 17th.

Read Our Latest Report on EBS

About Emergent BioSolutions

(Get Free Report)

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.